3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Uterine Cervical Neoplasms
2
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Endometrial Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Ovarian Epithelial
1
Adenocarcinoma of Lung
1
Interventions
pembrolizumab
13
Nivolumab
6
Gemcitabine
5
Paclitaxel
4
Cisplatin
4
Magnetic Resonance Spectroscopy
3
Ipilimumab
3
Fluorouracil
3
Fluorodeoxyglucose F18
3
Carboplatin
3
spartalizumab
2
fludarabine
2
budigalimab
2
Oxaliplatin
2
Leucovorin
2
Irinotecan
2
FAPI-46
2
Drug Therapy
2
Docetaxel
2
Cyclophosphamide
2
Bevacizumab
2
venetoclax
1
ulixertinib
1
tislelizumab
1
seribantumab
1
saracatinib
1
rovalpituzumab tesirine
1
pertuzumab
1
pemigatinib
1
nilotinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Cholangiocarcinoma
×
bemarituzumab
×
Gynecologic
×
Clear all
NCT05325866
2026-02-04
FORTITUDE-301
Amgen
Phase 1/2
Completed
260 enrolled